Positive Phase 1 Parkinson’s Trial Results of New Therapy Reported by Prothena
Prothena recently presented results from a Phase 1b clinical trial investigating a new antibody therapy for the treatment of Parkinson’s disease at the 13th​ International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) in Vienna, Austria. The trial was an ascending dose study of a novel antibody known as PRX002/RG7935.